UAE Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care) - Forecasts From 2023 To 2028

The UAE CGM market is expected to grow at a CAGR of 12.65%, from an initial value of US$3.645 million in 2021 to US$8.393 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Due to an increase in unhealthy lifestyles and other risk factors, diabetes is a fast-spreading illness that affects a significant portion of the population in the United Arab Emirates. The World Diabetes Federation estimates that the number of diabetics in the UAE would increase from 0.99 million in 2021 to 1.32 million in 2045. Individuals can reduce their risk of contracting this disease by adopting better lives and supporting expanding governmental measures. For patients hospitalized in hospitals with serious lung infections, controlling blood glucose levels become crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Also, throughout the forecast period, segment growth is anticipated to be fueled by the rising need for effective drug treatments for the treatment of diabetes.

Growing prevalence of Type-1 and Type-2 diabetes to surge growth.

As there is an increase in diabetic patients, there is an increase in continuous glucose monitoring systems. Also, there are various conveniences in testing blood glucose levels because of additional variables including technological improvements. Continuous glucose monitoring devices are one such development in blood glucose level monitoring. As a result, the market is anticipated to expand as more people with type 2 and type 1 diabetes use monitoring devices.

Technological advancements to surge growth.

Players in the global market are actively funding CGM research and technological development. The government's efforts to encourage local manufacturers to localize their production and to invite international companies in the healthcare sector to the nation assist the expansion of UAE continuous glucose monitoring devices. A further factor supporting the rise of the UAE glucometers market in the anticipated years is the general public's active investment in improved healthcare services and the need for modern monitoring tools that can help them maintain regular checks on their health issues.

Market Key Developments

• In August 2022, an alliance between Al-Futtaim Health and Abbott has been launched to raise advanced laboratory diagnostic standards in Dubai.
• In June 2022, The Dubai Branch of BD (Becton, Dickinson, and Company) (NYSE: BDX) and VPS Healthcare's Burjeel Medical City (BMC) today announced a strategic partnership that will allow both organizations to accelerate innovation and deliver healthcare excellence in the nation.

UAE Continuous Glucose Monitoring (CGM) Market Scope:

Segmentation:

• By Application
  • Diabetes Patients
  • Critical Patients
• By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. UAE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. UAE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES 

8.1. Abbott Laboratories

8.2. Medtronic plc

8.3. Dexcom, Inc.

8.4. Sanofi

8.5. Roche Diabetes Care, Inc.

8.6. Insulet Corporation

8.7. Novo Nordisk A/S

8.8. Becton, Dickinson, and Company

Abbott Laboratories

Medtronic plc

Dexcom, Inc.

Sanofi

Roche Diabetes Care, Inc.

Insulet Corporation

Novo Nordisk A/S

Becton, Dickinson, and Company